Recent Updates
Recently added Catalysts
IONS

Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis

Sunday, May 4, 2014 1 min read
Key Takeaway: Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis

Full Press Release Details

Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis.
Tags: IONS Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 4, 2014